We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Demonstration of the Presence of Circulating Tumor Cells as Evidence of Metastatic Potential—Reply

Ralf Steinert, MD; Marc A. Reymond, MD, MBA
Arch Surg. 2008;143(11):1134. doi:10.1001/archsurg.143.11.1134-b.
Text Size: A A A
Published online


In reply

We thank our colleagues Barreto and Shukla for their interest in our work and for their comments. They are right, the concept of circulating tumor cells is not new. In fact, circulating cells in blood were first described not in 1955 by Engell, but—to our knowledge—in 1917 by Marcus.1

Barreto and Shukla remark that disseminated cells are epithelial cells and that the labeling we used was not tumor-specific. This is correct. However, we had no better choice than these antibodies when our study started in 1997. Moreover, in the meantime, the markers we used have been applied in a large number of prognostic studies on minimal residual disease in various cancers. It is indeed unfortunate that no specific tumor markers are available for immunohistochemical characterization of circulating epithelial cells. This was the reason why our group started early molecular studies on this topic; we were the first to investigate the clonality of disseminated tumor cells of colorectal origin in bone marrow on the basis of mutations in the K-ras codons 12 and 13.2

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles